Table 1

Characteristics of patients included in this study

CharacteristicTotal (n=193)Male (n=114)Female (n=79)P value
Age (years)55.45±11.7353.25±12.2958.62±10.130.002
Duration (months)84(24,132)72(12,123)96(36,144)0.091
BMI (kg/m2)26.08±3.4226.66±3.0725.25±3.730.005
WHR0.94±0.060.95±0.050.92±0.060.001
Creatinine (mg/L)6.76±1.917.53±1.785.65±1.50<0.01
Cystatin C (mg/L)0.98±0.331.01±0.340.93±0.310.129
Cre/CysC7.26±2.067.86±2.076.38±1.71<0.01
Albumin (g/L)42.53±4.6242.97±4.4141.90±4.870.115
BUN (mmol/L)5.47±1.525.60±1.555.30±1.470.177
TG (mmol/L)1.45 (0.98,2.12)1.52 (1.16,2.27)1.23 (0.83,1.84)0.004
TCH (mmol/L)4.54±1.154.36±1.144.80±1.130.009
HDL (mmol/L)1.11±0.291.03±0.251.22±0.31<0.001
LDL (mmol/L)2.63±0.862.47±0.822.86±0.870.002
HbA1c (%)8.65±1.908.51±1.898.85±1.920.231
FBG (mmol/L)7.24±2.286.91±1.957.72±2.630.021
FCP (ng/mL)2.22±0.942.36±0.892.02±0.970.02
HOMA2 %B79.29±44.0587.89±44.7666.96±40.200.002
HOMA2 %S66.35±34.0862.20±29.5372.30±39.170.059
HOMA2 IR1.83±0.821.89±0.771.74±0.880.248
Hypertension (%)89 (46.11)54 (47.37)35 (44.30)0.675
CV disease (%)59 (30.57)29 (25.44)30 (37.97)0.063
DPN (%)147 (76.17)87 (76.32)60 (75.95)0.953
LEAD (%)109 (56.48)63 (55.26)46 (58.23)0.683
DN (%)82 (42.49)47 (41.23)35 (44.30)0.671
DR (%)44 (22.80)23 (20.18)21 (26.58)0.297
SMI (cm2/m2)47.80±8.7152.59±6.8140.87±6.11<0.001
MMA (HU)37.11±6.8239.14±5.9534.17±6.96<0.001
FMI (kg/m2)8.63±1.828.36±1.729.01±1.890.014
  • BMI, body mass index; BUN, blood urea nitrogen; Cre/CysC, creatinine-to-cystatin C ratio; CV, cardiovascular; DN, diabetic nephropathy; DPN, diabetic peripheral neuropathy; DR, diabetic retinopathy; FBG, fasting blood glucose; FCP, fasting C peptide; FMI, fat mass index; HbA1c, hemoglobin A1C; HDL, high-density lipoproteins; HOMA2, homeostasis model assessment; IR, Insulin resistance; LDL, low-density lipoproteins; LEAD, lower extremity arterial disease; MMA, mean skeletal muscle attenuation; SMI, skeletal muscle index; TCH, total cholesterol; TG, triglycerides; WHR, waist–hip ratio.